Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer

被引：0
|
作者：
M Gijsen
P King
T Perera
P Parker
B Larijani
A Harris
A Kong
机构：
[1] University of Oxford,Cancer Research UK
[2] Johnson & Johnson Pharmaceutical Research & Development,undefined
[3] London Research Institute,undefined
来源：
Breast Cancer Research | / 12卷
关键词：
Breast Cancer; Trastuzumab; Feedback Loop; Xenograft Model; Fluorescence Resonance Energy Transfer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Primary systemic therapy in HER2-amplified breast cancer: a clinical review
    Khasraw, Mustafa
    Bell, Richard
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (08) : 1005 - 1013
  • [42] Genetic testing in a cohort of young patients with HER2-amplified breast cancer
    Eccles, D. M.
    Li, N.
    Handwerker, R.
    Maishman, T.
    Copson, E. R.
    Durcan, L. T.
    Gerty, S. M.
    Jones, L.
    Evans, D. G.
    Haywood, L.
    Campbell, I.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 467 - 473
  • [43] Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+breast cancer
    Hu, Huizhong
    Simon, Lukas
    Qin, Lanfang
    Nardone, Agostina
    Shaw, Chad
    Chamness, Gary
    Heiser, Laura
    Wang, Nicholas
    Gray, Joe W.
    Osborne, C. Kent
    Schiff, Rachel
    CANCER RESEARCH, 2015, 75
  • [44] A JAK3/STAT3 passenger activation in a lapatinib-acquired resistance model of HER2-amplified breast cancer
    Van Bockstal, M.
    Van Roy, N.
    Vergauwen, G.
    Lambein, K.
    Cocquyt, V.
    Libbrecht, L.
    Denys, H.
    Bracke, M.
    De Wever, O.
    BREAST, 2017, 32 : S48 - S48
  • [45] Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer
    O'Brien, Carol
    Cavet, Guy
    Pandita, Ajay
    Hu, Xiaolan
    Haydu, Lauren
    Mohan, Sankar
    Toy, Karen
    Rivers, Celina Sanchez
    Modrusan, Zora
    Amler, Lukas C.
    Lackner, Mark R.
    CANCER RESEARCH, 2008, 68 (13) : 5380 - 5389
  • [46] Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan
    Yun, Karen M.
    Bazhenova, Lyudmila
    BMJ CASE REPORTS, 2023, 16 (05)
  • [47] A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
    Gang Ning
    Qihui Zhu
    Wonyoung Kang
    Hamin Lee
    Leigh Maher
    Yun-Suhk Suh
    Michael Michaud
    Mayerlin Silva
    Jee Young Kwon
    Chengsheng Zhang
    Charles Lee
    BMC Cancer, 21
  • [48] Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.
    Siena, Salvatore
    Sartore-Bianchi, Andrea
    Lonardi, Sara
    Trusolino, Livio
    Martino, Cosimo
    Bencardino, Katia
    Leone, Francesco
    Zagonel, Vittorina
    Valtorta, Emanuele
    Torri, Valter
    Siravegna, Giulia
    Amatu, Alessio
    Bonazzina, Erica Francesca
    Rusconi, Francesca
    Ghezzi, Silvia
    Ciardiello, Fortunato
    Veronese, Silvio
    Comoglio, Paolo Maria
    Bardelli, Alberto
    Marsoni, Silvia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Prognostic and predictive implications of monosomy 17 in curable HER2-amplified breast cancer
    Page, David
    Wen, Yong H.
    Dure, Dana
    Hudis, Clifford
    Brogi, Edi
    McArthur, Heather
    CANCER RESEARCH, 2015, 75
  • [50] A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer
    Ning, Gang
    Zhu, Qihui
    Kang, Wonyoung
    Lee, Hamin
    Maher, Leigh
    Suh, Yun-Suhk
    Michaud, Michael
    Silva, Mayerlin
    Kwon, Jee Young
    Zhang, Chengsheng
    Lee, Charles
    BMC CANCER, 2021, 21 (01)
12345